Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection - Test2 - elhamkhani - TriplyDB

Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection

Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection

http://www.wikidata.org/entity/Q36066494

about

Modeling the within-host dynamics of HIV infection How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?Clinical development of candidate HIV vaccines: different problems for different vaccines Might dolutegravir be part of a functional cure for HIV?Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research Perspectives for immunotherapy: which applications might achieve an HIV functional cure?Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV Residual Viremia in Treated HIV+ Individuals Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 Cellular superspreaders: an epidemiological perspective on HIV infection inside the body Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection.Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.The detection and management of early HIV infection: a clinical and public health emergency.The potential of radioimmunotherapy as a new hope for HIV patients.Immunologic strategies for HIV-1 remission and eradication.Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells Immune activation and HIV persistence: implications for curative approaches to HIV infection.Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?Quantifying the turnover of transcriptional subclasses of HIV-1-infected cells HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells Towards an HIV cure: a global scientific strategy Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy.Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapies Eradicating HIV-1 infection: seeking to clear a persistent pathogen.Immuno-modulatory strategies for reduction of HIV reservoir cells.Post-treatment control of HIV infection.Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission?HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells.Recombination Enhances HIV-1 Envelope Diversity by Facilitating the Survival of Latent Genomic Fragments in the Plasma Virus Population.Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral Therapy Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions.

P2860

Q21245370-EAC29524-BE33-4573-AC58-B5D37C72FE19 Q26822422-892DE001-3CFA-4051-A2C7-8EDE8B2882F6 Q27005008-79751E95-1626-41C9-99C1-F3D976AD265B Q28071420-6D7EB6BD-8D6B-4B0F-AAF5-3918CCF0F948 Q28077662-A81C83A9-E07D-4A06-B586-5FB364F913DF Q28078726-94944C87-D55A-4276-8B50-993CD1F9551A Q28384231-26D66F83-1B1A-404C-B03A-C1B8A7D61F54 Q28551642-3767AC6C-F201-4D91-B21A-9F922E388B27 Q28552126-82A1718D-D539-4370-A21F-904418C3F6D7 Q28655602-8B103F32-8492-4A24-AFF4-D2243007BF39 Q28657772-0FA1C945-2E2F-4770-82AC-343AF75367E8 Q30400191-CF8F7280-C18A-4600-AF98-2D646C2CE22C Q33585386-7063202E-6A2A-4165-815E-DCAF78BB484C Q33586581-5357B3F9-9FF7-4B6A-8EED-ACB717EB9CB8 Q33863509-000AF23B-C1E3-4E67-B88E-4E2064AFBD19 Q33896523-1F4821D0-9BE2-45B0-95A1-507486A8A238 Q34020988-6735F30E-830D-4C6C-9AB4-A885FFD89B20 Q34059612-FB3A7DAE-97D7-40A3-9405-17B0484F5DE3 Q34351320-B15C18B7-5E5A-46FE-BC91-1F2F36D1B3DC Q34379806-BBF3AE4A-8AE9-4DD3-A9EC-AB0273F1C54B Q34393716-1C0EEF68-FF28-4E0E-9459-362136757520 Q34430211-CB9A80E5-B4A1-4DBF-B095-8284D4F2301F Q34550046-B8D0720C-6BB5-4AC7-B047-F086C2F66E51 Q34594969-7D9C2B23-0D9E-4EF7-BD75-0375800994AF Q34640562-92DF2C72-C4F7-4B83-A5D3-60386446B45E Q35035926-56BAA71D-E68E-4838-A811-9603D5090B76 Q35072975-D5043D55-B071-4495-B773-90D62E45CFE7 Q35141776-D5825270-55B2-45A6-94A1-220E1CBC8B09 Q35252186-69912BE1-6470-4875-B112-DC5A7AC711B2 Q35329923-F4463283-AEE4-4C03-8F2D-4B5751CA1214 Q35567047-3BA88619-A433-4CD0-8872-857557801A3F Q35577906-A867CE6A-DC3A-45BC-8005-0F4B57F5F3F9 Q35595846-4AF32618-ACB8-4B61-95BF-7CA9319BD7E4 Q35680431-0B224BDB-9BF8-48E3-9271-1123C1AA551F Q35819184-0D82EAE5-6B14-4D16-8D27-A68AE44499FF Q35875253-2F0B6CC5-6259-439F-903F-A76804492DCA Q36030494-D5E6D28C-4A99-4E21-857D-DE2C4A18EE1C Q36030989-32006BA2-936D-43D6-AB46-41B61D7C8745 Q36038655-B65D56F0-B204-4861-BDA3-638E73C93C3A Q36113077-03D44B5F-9A05-40E4-9F66-DC0F03322063

P2860

Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection

http://www.wikidata.org/entity/Q36066494

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Immediate antiviral therapy ap ...... the decay of latent infection

@ast

Immediate antiviral therapy ap ...... the decay of latent infection

@en

type

label

Immediate antiviral therapy ap ...... the decay of latent infection

@ast

Immediate antiviral therapy ap ...... the decay of latent infection

@en

prefLabel

Immediate antiviral therapy ap ...... the decay of latent infection

@ast

Immediate antiviral therapy ap ...... the decay of latent infection

@en

P1433

Q36066494-EBB63841-D09C-4956-9676-B23825D5A354

P1476

Q36066494-591C003A-6D21-47DA-86C1-221F046C080C

P2093

Q36066494-11427B3D-A40D-449C-A968-8997BFA6ABD6

Q36066494-750DD09F-C195-418C-808B-EA17DCA21433

Q36066494-9CC7C495-470E-4D9F-A463-90A57B5DA76C

Q36066494-9D08545A-EC65-4B22-99FA-F75F2BF3FCC8

Q36066494-ADE7C6DC-786A-4450-92A5-9D503A1F1F37

Q36066494-B989DB20-98F7-48A0-9520-21A2C0DB977C

Q36066494-D7843368-F534-460E-8A6F-2655E581B2C3

Q36066494-FF51261C-2049-4792-879D-E134BD7F8004

P2860

Q36066494-033A1400-18F5-4877-A25D-2DDFF3E92ED5

Q36066494-036ACEB7-C8E9-41A4-B478-6C30A17EC91C

Q36066494-0829B53E-17B2-4636-9319-C1DD54C2DDAD

Q36066494-0FEC3E56-8D5A-4726-A460-4C9EC7982B00

Q36066494-16F1AF61-617B-44E8-9D5B-3CE71A919AB5

Q36066494-18441E0F-60BF-47DE-8941-D22888F8F5C3

Q36066494-1B628725-244F-496F-8FDB-D217889FDDDA

Q36066494-273FAED8-6CB8-4235-B2F8-F11AE13BEE4E

Q36066494-2A49E0D8-B4C2-4669-8834-9105E9FCCA39

Q36066494-3133E4A7-C489-4B89-8409-738516E874DE

P304

Q36066494-571202C8-78BD-49FA-B28E-F9CFE7337712

P31

Q36066494-2863BD95-EFFB-4A31-B753-CDFBC43EB89F

P356

Q36066494-3682A0B4-12DA-44CE-859B-111D3DCCBA2B

P407

Q36066494-3E2A22CF-DFE8-420E-B102-75B3D43C4B5A

P433

Q36066494-31C14D11-190E-45FC-B847-CD4E5D117280

P478

Q36066494-D1CCCCB8-F857-419D-8DEB-FEE9930346DC

P50

Q36066494-4888E614-0D1B-4A57-A376-409906D89229

Q36066494-8A240CB3-8E8D-4F6C-8102-97520D4A8750

Q36066494-A2AA4872-8443-4A2F-B7BB-B4C75F8AD4C1

Q36066494-F302563C-7CD4-4C4C-9629-9231D76883FE

Q36066494-FEE888B6-711A-45B6-B0E4-5C9D78C23DB1

P577

Q36066494-3C9BBFC3-1D61-469A-9C95-B3EA50C676ED

P5875

Q36066494-DF51EEB6-BF09-4A9A-BE2C-44CA5F971802

P698

Q36066494-4A6D19D4-2A89-42DB-A1B1-9E981D8C2727

P932

Q36066494-A1C378D2-6999-46D4-BAE8-1AACA0BDBFE7

P356

PNAS.1120248109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Immediate antiviral therapy ap ...... the decay of latent infection

@en

P2093

Abigail L Liberty

http://www.w3.org/2001/XMLSchema#string

Ann Wiegand

http://www.w3.org/2001/XMLSchema#string

Cynthia L Gay

http://www.w3.org/2001/XMLSchema#string

Joann D Kuruc

http://www.w3.org/2001/XMLSchema#string

John M Coffin

http://www.w3.org/2001/XMLSchema#string

Nancie M Archin

http://www.w3.org/2001/XMLSchema#string

Naveen K Vaidya

http://www.w3.org/2001/XMLSchema#string

Ronald J Bosch

http://www.w3.org/2001/XMLSchema#string

P2860

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection

High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

The challenge of viral reservoirs in HIV-1 infection

Viral and latent reservoir persistence in HIV-1-infected patients on therapy

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

P304

9523-9528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1120248109

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

David M. Margolis

Alan S. Perelson

P577

2012-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225074465

http://www.w3.org/2001/XMLSchema#string

P698

22645358

http://www.w3.org/2001/XMLSchema#string

P932

3386138

http://www.w3.org/2001/XMLSchema#string